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The system for local hyperthermia of cancers was simulated. This system is based on independently phased di-
poles with frequency 150 MHz. The electromagnetic field distributions are calculated in cut of tissue-equivalent 
phantom. It was shown that the electromagnetic field can be focused in desirable volume by means of independent 
vary of amplitude and phase of each dipole. The advantages of combined therapy are discussed for common using of 
hyperthermia with chemotherapy, radiation therapy or surgery. 
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1. INTRODUCTION 
Surgery, chemical therapy and radiation (gamma, 
electron or hadron) are three classical methods of the 
cancer treatment. They are used independently and in 
combination one another. But all tree methods have 
some limitation and negative after effects for patients. 
The decrease of such negative effects is one of main 
direction of contemporary oncology.  
So called hyperthermia (ancient Greek ὑπερ- − «ex-
cessively» and θέρμη − «heat») is one of possible meth-
ods to decrease negative after effects. The hyperthermia 
is kind of thermotherapy based on increasing tempera-
ture of body, body part or organ prone to pathological 
process. It was shown that combined chemical therapy 
and hyperthermia is very perspective because the medi-
cal preparation dose can be 2-3 times reduced [1-4]. 
Some types of cancer cells can be made more sensitive 
to the radiation using hyperthermia also. Developing 
and adoption of treatment methods when intensification 
chemotherapy effect takes place, in clinical practice is a 
primary target. The thermal effect lead to lysosome ac-
tivation, tissue breathing and protein synthesis inhibi-
tion, tissues pH decreasing, kariokynetic cycle modifi-
cation, trans membrane transfer improvement, sensitiza-
tion tumor cells to chemotherapy and growing up im-
munity. The temperature when volume blood flow in 
healthy tissues decreases as a result of progress dis-
seminated intravascular clotting is the limit of the ther-
motherapy usage. The hyperthermia is conventionally 
devisable into three temperature ranges: 
- 43…44°С – direct destruction of tumor; 
- 40…42°С – sensitization tumor cells to chemo-
therapy or radiotherapy; 
- 38…40°С – tumor size increasing is possible. 
Indeed, patient's heating to 44°С can lead to a num-
ber of pathological changes and progress of fatal com-
plication. That’s why the temperature 44°С during local 
hyperthermia is not reached yet. The heating mode 
41.5…42.1°С during 60…120 min are more often ap-
plied. There are several types of hyperthermia and re-
spectively several frequencies range: 
- Overall hyperthermia (10…15 MHz); 
- Regional hyperthermia (40…100 MHz); 
- Local, distant, intracavitary hyperthermia 
(100…200 MHz, 433 MHz, 915 MHz, 2.5…3 GHz); 
- Combined hyperthermia (overall + local); 
- Extra high frequency (EHF) therapy 
(30…300 GHz). 
Several heat-transfer materials (water, air) are used 
for overall hyperthermia in practice medicine. In that 
case the greatest temperature is reached on the body's 
surface that leads to a burn. 
2. HYPERTHERMIA COMBINED 
WITH RADIOTHERAPY 
There are a lot of works, where the synergism of hy-
perthermia and radiation effect on cancer’s growth is 
shown. It is assumed that modification effect of hyper-
thermia on radiation’s effect consists of next points [5]: 
1. Radiation’s sensitivity increasing; 
2. Decreasing of cell’s ability to regenerate sublethal 
and potential lethal damage; 
3. Selective influence to cells which are in radiore-
sistance phase of kariokynetic cycle. 
Blood flow increases with hyperthermia which leads 
to tissues saturation growth by oxygen and, conse-
quently, to higher sensitivity of cancer to the radiother-
apy. Radiosensitization’s effect of hyperthermia is de-
pended of sequence of heating and radiation application: 
the greatest effect is reached at their simultaneous appli-
cation. If radiotherapy precedes hyperthermia, regenera-
tion of radiation damages will take place at interaction 
with thermal damage. If hyperthermia precedes radio-
therapy, regeneration of thermal damage will takes 
place at interaction with radiation damage. The correla-
tion between this phenomenon and value of unprepared 
filamentous DNA rupture was shown [6]. 
3. HYPERTHERMIA COMBINED 
WITH CHEMOTHERAPY 
Hyperthermia and anticarcinogenic chemotherapeu-
tic medicine can acts independently, can supplement 
each other and perfectly cooperate. The major mecha-
nisms which provide anticarcinogenic chemotherapeutic 
medicine’s effect are the raised concentration of drug in 
a tumor. The concentration raise is a result of increasing 
blood supply and permeability of membranes, and also 
an increasing endocellular medicinal metabolism and 
reaction acceleration. 
There are four groups of chemical compounds which 
antineoplastic effect in the conditions of a hyperthermia 
is studied [7]. Drugs with linear cytotoxicity increasing 
versus of the temperature rise make the first group: al-
kylating agent (thiophosphamide), bifunctional alkylates 
(nitrosourea), mitomycin, cisplatin. A limit cytotoxicity 
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is proportional to the temperature for second group 
drugs. The accurate synergism of hyperthermia and 
chemotherapy appears for the temperature higher than 
42…43ºC. For example it is observed for adriamycin, 
bleomycin and actinomycin D. Third group consists of 
drugs which become cytotoxic only at high temperature 
(cystamine, amphotericin B). Drugs which have the 
constant cytotoxicity at temperature 37…45ºC (meth-
otrexate, fluorouracil, vincristine, and vinblastine) can 
be placed to the forth group. 
4. RADIOTHERAPY AND COMBINED 
THERAPY IN RUSSIAN ONCOLOGICAL 
SCIENTIFIC CENTER 
Combined therapy using the radiotherapy with the 
hyperthermia Thermo Radio Therapy, TRT) in RORC is 
spent since 1980. TRT was carried out more than 1000 
patients at present. 
The improved results of TRT in comparison with 
conventional radiotherapy (RT) are presented in Ta-
ble 1. The frequency of full regresses of localizations 
listed above is higher after TRT. Result’s analysis 
shows that the five-year survival rate after TRT is 
higher than after radiotherapy (Table 2). 
Table 1 
Frequency of full regression after radiotherapy 
or thermoradiotherapy courses 
Tumor’s localization TRT, % RT, % Statistic error 
Prostate cancer 94±2.3 69±8.2 
Soft tissue sarcoma 45±5.2 14±5.1 
Regional metastasis of 
neck epidermoid cancer 57±6 12±7.8 
Epidermoid anal channel 
cancer  100 60±21.9 
Extraabdomenal des-
moids cancer 33±7 0 
Relapse rectum cancer  24±6.3 5±4.9 
p<0.05 
The TRT treatment program is realized in RORC. 
Such program allows to sufficient and authoritative re-
duce of the regional cancer recrudescence and metasta-
ses comparatively to the surgery or independently radio-
therapy. As an example, the rectum cancer recrudes-
cence was observed for 0.9±0.6 % (2 form 220 patients) 
and metastases for 5 % (11 from 220 patients) compara-
tively with 16.2±1.9 % (64 form 395) for surgery and 
9.6±2.1 % (26 from 272) for surgery and before RT. 
Table 2 
Five-years survival rate after radiotherapy 
or thermoradiotherapy courses 
Tumor’s localization TRT, % RT, % Statistic error 
Prostate cancer 68±4.5 53±8.0 
Soft tissue sarcoma 46±5.2 35±7.0 
Regional metastasis of 
neck epidermoid cancer 24±4.2 9±4.6 
Epidermoid anal channel 
cancer  69±6.8 30±12.7 
Extraabdomenal des-
moids cancer 40±5.7 6±4.5 
p<0.05 
Relapse rectum cancer  68±4.5 53±8.0 p<0.01 
Indeed, the efficiency of TRT was shown for a num-
ber of cancer types in RORC. The local heating with 
41…45ºC temperature regime and 60 minutes duration is 
improved the RT results because of the cancer cells dam-
age and radio sensitization. Cancer treatment effect grows 
versus temperature and procedure time increasing.  
5. HYPERTHERMIA FACILITIES 
AND FREQUENCY RANGE CHOICE 
Facilities for overall and regional hyperthermia are 
manufacturing by some companies since 1980’s [8-10]. 
Federal state unitary enterprise "Research & production 
corporation "Istok" is the main manufacturer in Russia. 
The local hyperthermia became more useful as whole 
body hyperthermia at present. The local hyperthermia 
allows to focus the radiation in the local volume placed 
deep inside into human body and to prevent of other 
tissues or organs heating. 
Microwaves application is more perspective in com-
parison with optical and infrared waves because they 
having higher penetrating capacity in the human body 
perspective in the field of a hyperthermia. The RF fre-
quency range (100…200 MHz) is optimal because the 
wavelength in human body will approximately equal to 
the body’s size. Dielectric properties of biological tis-
sues at 150 MHz are shown in Table 3 [11].  
Table 3 
Dielectric properties of biological tissues 
in 150 MHz range 
 ε ρ, g/cm3 σ, S/m 
Muscle 62.8 1.047 0.72 
Bone 14.6 1.99 0.068 
Skin 63.5 1.125 0.53 
Blood 72.2 1.058 1.25 
Tumor 74 1.047 0.89 
Fat 5.84 0.95 0.037 
The blood is the most conductive tissue but blood in-
travascular clotting can not be a serious problem due to 
the blood flow. Dielectric properties of cancer are com-
parable with muscle’s one (they have same density, 
similar values of conductivity and relative permittivity). 
It’s should be taken into account at planning of the hy-
perthermia procedure in order to decrease damage ef-
fects on healthy tissues. Fat and bones have a less con-
ductivity in comparison with muscle and tumor. 
Now some USA, Germany and Netherlands compa-
nies are offer a number of local hyperthermia facilities 
but its price is very high (up to 8 MEuro). 
6. DIPOLE SYSTEM FOR LOCAL 
HYPERTHERMIA 
The antenna grid consisting of number independently 
phased dipoles is proposed for local hyperthermia of can-
cers. The operating frequency is chosen equal to 
150 MHz in R&D. The dipoles proposed are modification 
of well-known half-wave dipoles. The grid will consists 
of an array of such dipoles and hold on the cylindrical 
surface with diameter equal to 40 cm. Dipoles fed inde-
pendently by coax cable (for instance low loss cable as 
RG213) from amplifiers at frequency 150 MHz. Inde-
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pendent feeding is necessary to focus electromagnetic 
fields in local region. The focusing can be done by inde-
pendently operation phase and amplitude choice for each 
dipole in the grid. The tissue-equivalent phantom and 
heating dipoles grid are shown in Fig.1. 
 
Fig.1. Tissue-equivalent phantom and dipoles grid 
Distributions of EM field in transverse (a) and longitu-
dinal (b) cuts of heating model are presented in Fig.2.  
 a 
 b 
Fig.2. Electric field distributions in cuts of heating 
model: a – transverse cut; b – longitudinal cut 
It is clear, that the electric field maximum is located 
in the center of the tumor. It was reached by means of 
an especial choice of phase and amplitude values of the 
RF field in each dipole as it was noted above. The elec-
tric field distribution versus time (or RF field phase) is 
shown in Fig.3. The transversal size of heated spot 
(where electric field decreases in 2  times) is equal 
~7…8 cm, and the longitudinal size is equal 
~10…12 cm. In other words, heating volume is a vol-
ume of cylinder with a radius ~4 cm and length ~10 cm. 
The specific absorption rate (SAR) can be calculated 
if the electric field distribution in phantom is known. 
SAR is the measure of the rate energy which is absorb-
ing in the body when in is irradiating by RF electro-
magnetic field. It is defined as the power absorbed per 
mass of tissue. SAR can be calculated f as: 
 
2
ESAR σρ=
ur
  [W/kg],  (1) 
where σ is the electrical conductivity; E is the RMS 
electric field; ρ is the phantom density. 
Also we can calculate the rate of temperature in-
creasing in the tissue, if specific heat ci is known: 
 i
dTSAR c
dt
= . (2) 
Eq. (2) is rewritten taking no account the blood flow. 
SAR is equal 235.5 W/kg with RMS supply power of 
each dipole equal 60 W. This implies that some minutes 
will necessary to heat tumor to 8 K (the tumor heat ca-
pacity is equal to 3560 J kg-1 K-1). At the same time the 
temperature of healthy tissues will increases no more 
then 2.5 K. 
 
Fig.3. Electric field distribution versus time  
(or RF field phase) 
7. RF POWER FEEDING SCHEME 
As it was noted above, the RF power supply should 
be independed for each dipole. The RF power system 
schematic layout is shown in Fig.4: 1 – driving genera-
tor with input signal’s frequency range 100…300 MHz 
and input impedance 50 Ohm; 2 – 8-out power splitter 
(for example Mini-circuits ZBSC-8-82+); 3 – voltage-
controlled phase shifter (Mini-circuits JSPHS-150) with 
frequency range 100…150 MHz, phase range 180°, 
control voltage 0…12 V; 4 – solid state amplifier (Mit-
subishi RA60H1317M1A-101) with frequency range 
135…175 MHz, output power – 60 W, supply voltage – 
12.5 V, control GAP-pin voltage 12.5 V; 5 – RF di-
pole’s grid.  
The operating principle of such layout is the follow-
ing. The signal from driving generator has the constant 
frequency and splits into 8 channels. Then by means of 
controlled 8 phase shifters and 8 solid state amplifiers 
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we can adjust phase and amplitude of every signal. Due 
to these adjustments electric field focusing in the desire 
region is available.  
 
Fig.4. RF power system schematic layout 
Modern solid state amplifiers can derive the neces-
sary amplification and are simple and stable at opera-
tion. For example, solid state RF amplifier Mitsubishi 
RA60H1317M with amplify frequency range of 
135…175 MHz and supply voltage 12.5 V can be used 
to provide the necessary RF power (to 60 W) and SAR 
values. The control of RF power can be realized using 
amplifier’s GAP channel which provide the turn on/off 
of amplifier.  
Indeed the 8 dipole antenna grid should be controlled 
by 16 voltage signals (8 for amplifiers and 8 for phase 
shifters). The low-voltage control system connected to 
PS should be designed future. 
CONCLUSIONS 
Combined therapy using the hyperthermia with the 
radiotherapy of the chemotherapy is very perspective 
methods of the cancer treatment. The efficiency of com-
bined therapy is evaluated on practice. The local hyper-
thermia became more useful as whole body and regional 
hyperthermia at present. The array of half wave dipoles 
is proposed for local hyperthermia. It was shown that 
the localization of heating in ~ 4×10 cm volume can be 
realized using this scheme. It was calculated that some 
minutes is necessary for tissue heating on 8 K (from 
36.6 to 44°С) with 60 W of RF power in each dipole. 
A number of problems should be solved before in-
troducing the facility in the clinical trials: 
1. 3D-models of body should be done using MRI 
and PET-CT scanning and correct tissue model should 
be simulated. In other words, after determining of tumor 
localization by means of scanning, it is necessary to 
simulate the computer model in which all tissues will be 
marked out. It is necessary because all tissues have per-
sonal dielectric properties. The thermodynamic problem 
should be solved using 3D model of RF field. 
2. Software for fast 3D simulation of electromag-
netic fields distribution should be developed. This soft-
ware should include the heating process simulation. 
3. Correct and low traumatic methods of temperature 
control are necessary.  
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РАЗРАБОТКА УСТАНОВОК ДЛЯ КОМБИНИРОВАННОЙ ТЕРАПИИ ОНКОЛОГИЧЕСКИХ 
ЗАБОЛЕВАНИЙ 
А.М. Фадеев, С.М. Иванов, Е.А. Перельштейн, С.М. Полозов, С.И. Ткачев  
Проведено моделирование работы системы для локальной гипертермии онкологических заболеваний на 
основе системы независимо фазируемых дипольных излучателей, работающих на частоте 150 МГц. Получе-
ны картины распределения электрических полей в сечении облучаемого образца (тканеэквивалентного фан-
тома). Показана возможность фокусировки электромагнитного поля в необходимом объеме за счет незави-
симого изменения фазы и амплитуды излучения каждого из диполей. Рассмотрены перспективы комбиниро-
ванного использования гипертермии и химической или лучевой терапии и хирургии. 
РОЗРОБКА УСТАНОВОК ДЛЯ КОМБІНОВАНОЇ ТЕРАПІЇ ОНКОЛОГІЧНИХ ЗАХВОРЮВАНЬ 
О.М. Фадєєв, С.М. Іванов, Є.А. Перельштейн, С.М. Полозов, С.І. Ткачов  
Проведено моделювання роботи системи для локальної гіпертермії онкологічних захворювань на основі 
системи незалежно фазіруємих дипольних випромінювачів, що працюють на частоті 150 МГц. Отримано 
картини розподілу електричних полів у перерізі опромінюваного зразка (тканееквівалентного фантома). По-
казана можливість фокусування електромагнітного поля в необхідному об’ємі за рахунок незалежної зміни 
фази і амплітуди випромінювання кожного з диполів. Розглянуто перспективи комбінованого використання 
гіпертермії та хімічної або променевої терапії та хірургії. 
